Antagonizing the renin-angiotensin-aldosterone system in the era of COVID-19

Intern Emerg Med. 2020 Aug;15(5):885-887. doi: 10.1007/s11739-020-02365-5. Epub 2020 May 18.

Riccardo Sarzani^{1

2

3}, Federico Giulietti^{4

5}, Chiara Di Pentima^{4

5}, Andrea Filipponi^{4

5}, Francesco Spannella^{4

5}

¹ Internal Medicine and Geriatrics, "Hypertension Excellence Centre" of the European Society of Hypertension, IRCCS INRCA, Ancona, Italy. r.sarzani@univpm.it.
² Department of Clinical and Molecular Sciences, University "Politecnica delle Marche", Ancona, Italy. r.sarzani@univpm.it.
³ Internal Medicine and Geriatrics, Department of Clinical and Molecular Sciences, Italian National Research Centre on Aging, Hospital "U. Sestilli", University "Politecnica delle Marche", IRCCS INRCA, via della Montagnola n. 81, 60127, Ancona, Italy. r.sarzani@univpm.it.
⁴ Internal Medicine and Geriatrics, "Hypertension Excellence Centre" of the European Society of Hypertension, IRCCS INRCA, Ancona, Italy.
⁵ Department of Clinical and Molecular Sciences, University "Politecnica delle Marche", Ancona, Italy.

No abstract available

Publication types